Victory Capital Management
XERS icon

Victory Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Victory Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
18,331
+491
+3% +$3.26K ﹤0.01% 2270
2025
Q4 		$140K Buy
17,840
+585
+3% +$4.6K ﹤0.01% 2244
2025
Q3 		$140K Sell
17,255
-353
-2% -$2.35K ﹤0.01% 2259
2025
Q2 		$82.2K Buy
17,608
+484
+3% +$2.22K ﹤0.01% 2346
2025
Q1 		$94K Sell
17,124
-361
-2% -$1.46K ﹤0.01% 2315
2024
Q4 		$59.3K Sell
17,485
-33
-0.2% -$106 ﹤0.01% 2374
2024
Q3 		$49.9K Sell
17,518
-366
-2% -$940 ﹤0.01% 2393
2024
Q2 		$40.2K Buy
17,884
+529
+3% +$1.07K ﹤0.01% 2387
2024
Q1 		$38.4K Sell
17,355
-99
-0.6% -$256 ﹤0.01% 2397
2023
Q4 		$41K Buy
17,454
+3,343
+24% +$6.17K ﹤0.01% 2456
2023
Q3 		$26.2K Buy
14,111
+413
+3% +$946 ﹤0.01% 2434
2023
Q2 		$35.9K Sell
13,698
-319
-2% -$812 ﹤0.01% 2418
2023
Q1 		$22.8K Sell
14,017
-487
-3% -$610 ﹤0.01% 2500
2022
Q4 		$19.3K Sell
14,504
-6
-0% -$8 ﹤0.01% 2513
2022
Q3 		$23K Sell
14,510
-2,245
-13% -$3.71K ﹤0.01% 2617
2022
Q2 		$26K Sell
16,755
-62
-0.4% -$131 ﹤0.01% 2597
2022
Q1 		$41K Buy
16,817
+852
+5% +$2.08K ﹤0.01% 2610
2021
Q4 		$47K Buy
+15,965
New +$34.5K ﹤0.01% 2648
2021
Q2 		– Sell
-10,236
Closed -$46K – 2815
2021
Q1 		$46K Buy
+10,236
New +$55.2K ﹤0.01% 2673
2020
Q2 		– Sell
-10,912
Closed -$22K – 3305
2020
Q1 		$22K Buy
+10,912
New +$46.9K ﹤0.01% 3065
2019
Q4 		– Sell
-3,105
Closed -$31K – 3298
2019
Q3 		$31K Buy
+3,105
New +$34.9K ﹤0.01% 2894
2019
Q2 		– Sell
-3,454
Closed -$35K – 1864
2019
Q1 		$35K Hold
3,454
– – ﹤0.01% 1727
2018
Q4 		$59K Hold
3,454
– – ﹤0.01% 1680
2018
Q3 		$61K Buy
3,454
+454
+15% +$9.85K ﹤0.01% 1709
2018
Q2 		$57K Buy
+3,000
New +$58.3K ﹤0.01% 1749

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management's XERS Position: Q1 2026 in Review

Victory Capital Management increased its Xeris Biopharma Holdings (XERS) stake by 2.8% in Q1 2026, buying an estimated $3.26K and bringing the position to 18,331 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Victory Capital Management first reported a position in XERS in Q2 2018 and has held it in 25 quarters since. The position peaked at $140K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Victory Capital Management held 18,331 shares of Xeris Biopharma Holdings worth $106K as of Q1 2026.
  • Victory Capital Management bought 491 Xeris Biopharma Holdings shares in Q1 2026, an estimated $3.26K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2270 holding.
  • Victory Capital Management first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 25 quarters since.
  • Victory Capital Management's Xeris Biopharma Holdings position peaked at $140K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.